Biotech Values

[DewDiligence]

MTEM -24% on Takeda’s dumping TAK-169 program:

https://finance.yahoo.com/news/molecular-templates-prioritize-next-generation-110000001.html

Molecular Templates…today announced that, following discussion with its co-development partner Takeda, MTEM will assume full rights to TAK-169 including taking control of clinical development from Takeda. In addition, MTEM announced the decision to discontinue development of MT-3724, MTEM’s only first-generation ETB. MTEM will focus on the clinical development of next-generation ETBs MT-5111, TAK-169, and MT-6402, as well as advancing next-generation preclinical ETB candidates against targets including CTLA-4, CD20, SLAMF-7 and CD45.